Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
Ardelyx (NASDAQ: ARDX) announced that President and CEO Mike Raab will participate in a fireside chat at the Wedbush Rewind ASN 2025 Conference on Monday, November 10, 2025 from 11:30 a.m. to 12:00 p.m. ET.
The session will be available via a public webcast on Ardelyx's Events and Presentations webpage, and a replay will be posted on the Ardelyx website for 30 days after the event.
Ardelyx (NASDAQ: ARDX) ha annunciato che il presidente e amministratore delegato Mike Raab parteciperà a una chiacchierata informale al Wedbush Rewind ASN 2025 Conference lunedì 10 novembre 2025 dalle 11:30 alle 12:00 ET.
La sessione sarà disponibile tramite webcast pubblico sulla pagina Eventi e Presentazioni di Ardelyx, e una riproduzione sarà pubblicata sul sito di Ardelyx per 30 giorni dopo l'evento.
Ardelyx (NASDAQ: ARDX) anunció que el presidente y director ejecutivo Mike Raab participará en una charla junto al fuego en la Conferencia Wedbush Rewind ASN 2025 el lunes 10 de noviembre de 2025 desde las 11:30 a. m. a 12:00 p. m. ET.
La sesión estará disponible a través de una transmisión pública en la página Eventos y Presentaciones de Ardelyx, y se publicará una repetición en el sitio web de Ardelyx durante 30 días después del evento.
Ardelyx (NASDAQ: ARDX)는 사장 겸 최고경영자 Mike Raab가 Wedbush Rewind ASN 2025 Conference의 파이어사이드 채팅에 참여할 것이라고 발표했습니다. 날짜는 2025년 11월 10일 월요일이며 시간은 동부 표준시 기준 11:30 a.m. ~ 12:00 p.m.입니다.
세션은 Ardelyx의 Events and Presentations 페이지에서 공개 webcast로 이용 가능하며, 이벤트 후 30일 동안 Ardelyx 웹사이트에 재방송이 게시될 예정입니다.
Ardelyx (NASDAQ: ARDX) a annoncé que le président et directeur général Mike Raab participera à une conversation informelle lors de la Wedbush Rewind ASN 2025 Conference le lundi 10 novembre 2025 de 11h30 à 12h00, heure de l’Est.
La session sera disponible via une diffusion publique sur la page Events and Presentations d'Ardelyx, et une rediffusion sera publiée sur le site d'Ardelyx pendant 30 jours après l’événement.
Ardelyx (NASDAQ: ARDX) gab bekannt, dass der Präsident und CEO Mike Raab an einem Fireside-Chat bei der Wedbush Rewind ASN 2025 Conference am Montag, 10. November 2025 von 11:30 Uhr bis 12:00 Uhr ET teilnehmen wird.
Die Session wird über einen öffentlichen Webcast auf der Ardelyx-Website unter Events and Presentations verfügbar sein, und eine Wiederholung wird auf der Ardelyx-Website für 30 Tage nach der Veranstaltung veröffentlicht.
Ardelyx (NASDAQ: ARDX) أعلنت أن الرئيس والمدير التنفيذي Mike Raab سيشارك في جلسة دردشة Fireside في Wedbush Rewind ASN 2025 Conference يوم الإثنين 10 نوفمبر 2025 من 11:30 صباحاً حتى 12:00 ظهراً بتوقيت شرق الولايات المتحدة.
سيتم الوصول إلى الجلسة عبر بث مباشر عام على صفحة Ardelyx Events and Presentations، وسيتم نشر إعادة للبث على موقع Ardelyx لمدة 30 يوماً بعد الحدث.
- None.
- None.
WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that President and CEO, Mike Raab will participate in a fireside chat at the Wedbush Rewind ASN 2025 Conference on Monday, November 10, 2025 from 11:30 a.m. to 12:00 p.m. ET.
To access the public webcast of the event, please visit the Events and Presentations page within the Ardelyx website at https://ardelyx.com/. A replay of the event will be available on the Ardelyx website for 30 days following the event.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as well as early-stage pipeline candidates. The company is developing RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contacts:
Caitlin Lowie
clowie@ardelyx.com